雌激素受体1(ESR1)XbaI基因多态性可能影响乳腺癌易感性;先前发表的研究结果不一致.本荟萃分析旨在探讨ESR1XbaI多态性与乳腺癌发病风险的关系。方法:来自PubMed的文章,Embase,科克伦图书馆,WOS,Scopus,万方数据,CNKI,系统搜索CBM和CQVIP数据库以确定ESR1XbaI多态性与乳腺癌风险之间的关联。使用比值比(OR)和95%置信区间(CI)评估合并结果,其次是亚组分析。结果:分析了22项研究,涉及12,821例病例和14,739例对照受试者。汇总结果表明,ESR1XbaI多态性可能降低AG患者患乳腺癌的风险。AA(共显性模型:OR=0.88,95%CI=0.79-0.97,P=0.015)和AGGGvs.AA模型(优势模型:OR=0.89,95%CI=0.80-0.98,P=0.022)。亚组分析表明,在亚洲受试者中观察到ESR1XbaI多态性与乳腺癌风险之间存在显着关联。非Hardy-Weinberg均衡研究,绝经后状态和AG下基于医院的亚组与AA和AG+GGvs.AA模型(均P<0.05)。结论:我们对汇总数据的分析表明,在某些亚组中,ESR1XbaI中的AG基因型可能是乳腺癌患者的保护因素。
Estrogen receptor 1 (ESR1) XbaI polymorphisms may affect breast cancer susceptibility; however, the results of previously published studies are inconsistent. This meta-analysis aimed to investigate the relationship between ESR1 XbaI polymorphism and breast cancer risk. Methods: Articles from the PubMed, Embase, Cochrane Library, WoS, Scopus, Wanfang Data, CNKI, CBM and CQVIP databases were systematically searched to determine the association between ESR1 XbaI polymorphism and breast cancer risk. The pooled results were assessed using odds ratios (ORs) and 95% confidence intervals (CIs), followed by subgroup analysis. Results: Twenty-two studies involving 12,821 cases and 14,739 control subjects were analyzed. The pooled results indicated that ESR1 XbaI polymorphism may decrease risk of breast cancer in AG vs. AA (co-dominant model: OR = 0.88, 95% CI = 0.79-0.97, P = 0.015) and AG + GG vs. AA models (dominant model: OR = 0.89, 95% CI = 0.80-0.98, P = 0.022). Subgroup analysis indicated significant associations between the ESR1 XbaI polymorphism and breast cancer risk were observed in Asian subjects, non-Hardy-Weinberg equilibrium study, post-menopausal status and hospital-based subgroups under the AG vs. AA and AG + GG vs. AA models (all P < 0.05). Conclusions: Our analysis of pooled data indicated that AG genotype in ESR1 XbaI may be a protective factor for breast cancer patients in some subgroups.